Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Now there is a new trial (SUPERNOVA) of an updated mix of monoclonal antibodies that hopes to provide durable protection against present and future variants of concerns.
June 2023 CLL Bloodline: The CLL Society Bloodline will teach the BASICS needed to understand CLL.
BTK inhibitors have revolutionized the care of CLL / SLL patients and profoundly improved outcomes
The combination of ibrutinib plus venetoclax is an effective first-line treatment for high-risk chronic lymphocytic leukemia (CLL)
Dr. Ed Ratner’s Review of For Blood and Money by Nathan Vardi that chronicles the development of two blockbuster drugs
Early results from a phase 1b/2 trial show that epcoritamab has a manageable safety profile and an encouraging response rate in patients with Richter syndrome.
A novel PROTAC-based BCL-2/BCL-XL degrader was able to cause cell death in laboratory models of venetoclax-resistant chronic lymphocytic leukemia (CLL).
Two years into the pandemic, CLL caregivers continued to cope with distress, live in isolation, and lose in-person care opportunities. They experienced increasing caregiving burden, shock, and devastation when a vaccine did not work for their loved one with CLL.
Fixed duration combination therapy of obinutuzumab, ibrutinib, and venetoclax with treatment adjustment based on clinical response and results of measurable residual disease testing shows high efficacy and safety for the front-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL / SLL) patients with del (17p) or TP53 mutation offering exciting hope for what has been an unmet need for this group of patients with high-risk disease.
One click to our most popular content.
